Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 6—June 2011

Dispatch

Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland

Alain Kenfak-Foguena1, Franziska Schöni-Affolter1, Philippe Bürgisser, Andrea Witteck, Katharine E.A. Darling, Helen Kovari, Laurent Kaiser, John-Marc Evison, Luigia Elzi, Vanina Gurtner De La Fuente, Josef Jost, Darius Moradpour, Florence Abravanel, Jacques Izopet2, Matthias Cavassini2Comments to Author , and the Swiss HIV Cohort Study
Author affiliations: Author affiliations: Centre Hospitalier Universitaire Vaudois and Lausanne University, Lausanne, Switzerland (A. Kenfak-Foguena, P. Bürgisser, K.E.A. Darling, D. Moradpour, M. Cavassini); Data Center of the Swiss HIV Cohort Study, Lausanne (F. Schöni-Affolter); Cantonal Hospital St. Gallen, St. Gallen, Switzerland (A. Witteck); University of Zurich, Zurich, Switzerland (H. Kovari); University Hospital Geneva, Geneva, Switzerland (L. Kaiser); Inselspital Klinik und Poliklinik für Infektiologie, Bern, Switzerland (J.-M. Evison); Universitätsspital Klinik für Infektiologie, Basel, Switzerland (L. Elzi); Ospedale Civico Servizio Malattie Infettive, Lugano, Switzerland (V. Gurtner-De La Fuente); Klinik Im Park, Zurich (J. Jost); Centre Hospitalier Universitaire de Toulouse, Toulouse, France (F. Abravanel, J. Izopet)

Main Article

Table 1

Population characteristics in a study of prevalence and role of HEV infection among participants in the Swiss HIV Cohort Study, Switzerland, 2008*

Characteristic No. (%) all participants, N = 735 No. (%) HEV negative,
n = 716 No. (%) HEV positive, n = 19 p value
Sex 0.0587
M 618 (84.1) 605 (84.5) 13 (68.4)
F
117 (15.9)
111 (15.5)
6 (31.6)

Ethnic group <0.0001
White 607 (82.6) 594 (83.0) 14 (73.7)
Black 70 (9.5) 69 (9.6) 1 (5.3)
Hispanic 26 (3.5) 25 (3.5) 1 (5.3)
Asian 29 (3.9) 26 (3.6) 3 (15.8)
Other
3 (0.4)
2 (0.28)
1 (0.14)

Probable route of HIV infection NS
Heterosexual 291 (39.6) 283 (39.5) 8 (42.1)
MSM 411 (55.9) 400 (55.9) 11 (57.9)
IDU 4 (0.6) 4 (0.6) 0
Blood 5 (0.7) 5 (0.7) 0
Unknown/other
24 (3.2)
24 (3.4)
0

Current or past IDU NS
Yes 14 (2.3) 14 (2.0) 0
No
721 (99.7)
702 (98.0)
19 (100.0)

Prison history NS
Yes 45 (6.1) 44 (6.1) 1 (5.3)
No
690 (93.9)
672 (93.9)
18 (94.7)

Alcohol consumption NS
Yes 261 (35.5) 256 (35.8) 5 (26.3)
No
474 (64.5)
460 (64.2)
14 (73.7)

BMI group, kg/m2 NS
<25 408 (55.5) 398 (55.6) 10 (52.6)
25.1–30 231 (31.4) 225 (31.4) 6 (31.6)
>30
96 (13.1)
93 (12.9)
3 (15.8)

ALT peak value, IU/L NS
<180 606 (82.4) 591 (82.5) 15 (78.95)
>180
129 (17.6)
125 (17.5)
4 (21.05)

Lowest CD4 count, cells/mm3 0.0685
<100 276 (37.6) 273 (38.1) 3 (15.8)
100–350 288 (39.2) 276 (38.6) 12 (63.2)
>350
171 (23.2)
167 (23.3)
4 (21.1)

HAART history NS
Yes 610 (83.0) 595 (75.4) 15 (78.9)
No
125 (17.0)
121(16.9)
4 (21.6)

Cancer occurrence NS
Yes 25 (3.4) 24 (3.4) 1 (5.3)
No
710 (96.6)
692 (94.6)
18 (94.7)

Outcome NS
Dead 29 (3.9) 28 (3.9) 1 (5.3)
Alive 652 (88.7) 638 (89.1) 14 (73.7)
Lost to follow-up 54 (7.4) 50 (7.0) 4 (21.1)

*HEV, hepatitis E virus; MSM, men who have sex with men; IDU, intravenous drug use; BMI, body mass index; ALT, alanine aminotransferase; HAART, highly active antiretroviral therapy; NS, not significant.

Main Article

1These authors contributed equally to this article.

2These authors contributed equally to this article.

TOP